RxDoctor Payments Data

Bonnie Clark, NP

Family · Jeffersonville, INNPI 1831472133

Payments from drug & device makers

$3,577in general payments, 2019–2025

Across 96 payments — averaging $37.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Insmed, Inc.$160
  • SK Life Science, Inc.$125
  • Lundbeck LLC$125
  • Boston Scientific$121
  • GSK$120
  • plus $334 from 9 others

What the payments were for

  • Food & beverage$3,53099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,577 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$3,938
Medicare patients
13
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$45,045
RexultiBrexpiprazole15$18,315
TrintellixVortioxetine Hydrobromide19$9,140
Memantine Hcl ErMemantine Hcl41$2,786
Mirtazapine24$1,065
Quetiapine Fumarate42$746
Divalproex Sodium39$598
Olanzapine24$523
Sertraline Hcl39$371
Buspirone Hcl19$239
Trazodone Hcl36$220
Hydroxyzine Hcl20$186
Zonisamide14$167
Propranolol Hcl30$165
Lamotrigine26$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,592$45,04531 claims
Lilly USA, LLCOlanzapine$12$52324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.

Other family in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →